THRIVE:Veligrotug治疗活动性甲状腺眼病的3期随机双盲安慰剂对照研究
THRIVE是一项全球多中心3期随机双盲安慰剂对照试验,评估Veligrotug(IGF-1R全拮抗单克隆抗体)治疗中重度活动性甲状腺眼病。113例患者按2:1随机接受Veligrotug 10 mg/kg或安慰剂,每3周静脉输注1次共5次。第15周Veligrotug组眼球突出应答率70%对5%,总体应答率67%对5%,复视改善59%对20%,复视完全缓解49%对12%(P<0.001)。第52周70%初始应答者维持眼球突出应答,药物总体耐受良好,治疗中断率4%。
要点
- Veligrotug 10 mg/kg每3周静脉输注共5次,第15周眼球突出应答率70%对5%(P<0.001)。
- 第15周复视改善59%对20%、复视完全缓解49%对12%,第52周70%初始应答者维持眼球突出应答。
- 药物总体耐受良好,治疗中断率4%,无严重治疗相关不良事件,52周安全性无变化。
核心结论
- 12周内5次Veligrotug输注总体耐受良好,可快速显著改善复视、眼球突出和疾病活动度,疗效维持至第52周。
- Veligrotug可能成为活动性甲状腺眼病有前景的新治疗选择。
研究设计与样本
- THRIVE为全球多中心、随机、双盲、安慰剂对照3期试验。
- 纳入中重度活动性TED成人患者(起病≤15个月、眼球突出≥3 mm、CAS≥3),按2:1随机接受Veligrotug 10 mg/kg或安慰剂,每3周静脉输注1次共5次。
- 共113例患者接受治疗,Veligrotug组75例、安慰剂组38例,两组基线特征均衡,疗效与安全性评估至第52周。
主要发现
- 第3周即观察到改善,第15周Veligrotug组所有主要和次要终点均显著优于安慰剂(P<0.001)。
- Hertel眼球突出应答率70%对5%,MRI/CT眼球突出应答率71%对9%,总体应答率67%对5%。
- 平均眼球突出减少:Hertel法2.90 mm对0.48 mm,MRI/CT法2.96 mm对0.58 mm。
- 复视改善59%对20%,复视完全缓解49%对12%。
- 第52周70%初始应答者维持眼球突出应答。
关键数值与推荐
- 眼球突出应答定义为Hertel突眼计测量眼球突出减少≥2 mm。
- 总体应答定义为眼球突出应答且CAS减少≥2分。
- 入组标准:起病≤15个月、眼球突出≥3 mm、CAS≥3。
- 给药方案:Veligrotug 10 mg/kg每3周静脉输注1次共5次。
临床怎么用
- 对中重度活动性TED患者,Veligrotug 5次输注方案可在第3周起快速改善眼球突出、复视和疾病活动度。
- 疗效可维持至第52周,治疗中断率4%,多数不良事件轻微且可缓解,无严重治疗相关不良事件。
局限性
- 主要终点指标(眼球突出应答率或总体应答率)因地理区域而异。
- 样本量113例,Veligrotug组75例、安慰剂组38例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Thyroid eye disease (TED) is a debilitating autoimmune disease with significant unmet needs. This study's objective was to assess the efficacy and safety of veligrotug, a full antagonist monoclonal antibody to the insulin-like growth factor-1 receptor, in patients with active TED. DESIGN: Veligrotug was assessed in THRIVE, a global, multicenter, randomized, double-masked, placebo-controlled phase 3 trial. PARTICIPANTS: Adult patients with moderate-to-severe active TED (onset ≤ 15 months, proptosis ≥ 3 mm above normal, and clinical activity score [CAS] ≥ 3) received either veligrotug or placebo. METHODS: Patients were randomized 2:1 to receive 10 mg/kg veligrotug or placebo administered every 3 weeks for a total of 5 IV infusions. MAIN OUTCOME MEASURES: The primary end point at week 15 was the proptosis responder rate (PRR; ≥ 2-mm reduction by Hertel exophthalmometry) or overall responder rate (ORR; PRR and ≥ 2-point reduction in CAS), depending on geographic region. Efficacy and safety were assessed through week 52. RESULTS: A total of 113 patients received veligrotug (n = 75) or placebo (n = 38). Baseline characteristics were balanced between the 2 arms. Improvements were observed at week 3, with a significantly greater response at week 15 for veligrotug versus placebo (P < 0.001) across all primary and secondary end points including: PRR by Hertel, 70% versus 5%; PRR by magnetic resonance imaging (MRI) or computed tomography (CT), 71% versus 9%; ORR, 67% versus 5%; mean proptosis reduction, 2.90 mm versus 0.48 mm (Hertel) and 2.96 mm versus 0.58 mm (MRI/CT); diplopia improvement, 59% versus 20%; and diplopia resolution, 49% versus 12%. At week 52, 70% of initial responders maintained proptosis response. Veligrotug was generally well tolerated, with a 4% treatment discontinuation rate. Most adverse events were mild and resolved, with no serious treatment-related adverse events and no changes in the safety profile through week 52. CONCLUSIONS: A 5-infusion course of veligrotug administered over 12 weeks was generally well tolerated and led to rapid and significant improvements in diplopia, proptosis, and disease activity, with a durable response through week 52. Veligrotug may become a promising new treatment option for active TED. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Yen MT, Cockerham K, Saeed P, et al. THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease. Ophthalmology. 2026. PMID: 42223386. doi:10.1016/j.ophtha.2026.04.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。